Get the Stockscreener App
1.77
3.28%
-0.06
After Hours:
1.77
Acrivon Therapeutics Inc stock is traded at $1.77, with a volume of 576.31K.
It is down -3.28% in the last 24 hours and up +16.45% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.83
Open:
$1.84
24h Volume:
576.31K
Relative Volume:
0.49
Market Cap:
$55.68M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.6367
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
-7.33%
1M Performance:
+16.45%
6M Performance:
+9.26%
1Y Performance:
-75.72%
1-Day Range:
$1.71
$1.90
1-Week Range:
$1.71
$2.02
52-Week Range:
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.77 | 57.56M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Is Acrivon Therapeutics Inc. still worth holding after the dipIndex Update & Fast Momentum Entry Tips - newser.com
News impact scoring models applied to Acrivon Therapeutics Inc.July 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - newser.com
How Acrivon Therapeutics Inc. stock valuations compare to rivalsMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com
What Fibonacci levels say about Acrivon Therapeutics Inc. reboundPortfolio Value Report & Fast Moving Stock Trade Plans - newser.com
Is Acrivon Therapeutics Inc. stock positioned well for digital economyPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Acrivon Therapeutics (NASDAQ:ACRV) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Sector ETF performance correlation with Acrivon Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - 富途牛牛
Risk vs reward if holding onto Acrivon Therapeutics Inc.July 2025 Market Mood & Safe Entry Trade Reports - newser.com
Will Acrivon Therapeutics Inc. stock benefit from sector rotationInflation Watch & Fast Entry Momentum Alerts - newser.com
What to expect from Acrivon Therapeutics Inc. in the next 30 daysJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 127.8% - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 127.8% in September - MarketBeat
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan
Acrivon Therapeutics, Inc. $ACRV Holdings Decreased by Goldman Sachs Group Inc. - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $15.00 - Defense World
Tools to assess Acrivon Therapeutics Inc.’s risk profileTreasury Yields & Stepwise Trade Signal Guides - newser.com
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):